Mounjaro's 4-dose pen format: what arrives, how it's used, and what to expect

You open the box and find one pen. Here's why that covers the whole month.

Picture the moment your delivery lands, DPD tracking has pinged, the box is plain, unbranded, and inside is a single pre-filled KwikPen. Nothing else needs counting. The pen is factory-set to deliver exactly one dose per weekly injection, and because there are four doses loaded, finishing the pen lines up almost perfectly with your next prescription review.

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means it acts on two gut-hormone pathways simultaneously. In practical terms, it slows how quickly food moves out of your stomach and signals to your brain that you've eaten enough sooner. These effects are dose-dependent, which is why the licensed schedule in the UK starts at 2.5 mg and moves upward: the first pen's job is to give your body time to adjust, not to deliver the full therapeutic effect right away. The prescriber titrates from there, usually in four-week steps.

The Mounjaro dosing schedule matters here because it determines which pen strength you receive at each stage. You'll move through 2.5 mg, then 5 mg, 7.5 mg and so on toward the higher doses, but always one pen at a time, each covering one month. The NHS tirzepatide information page gives a plain-English overview of how the medicine works if you'd like background reading before your first injection.

One practical note on the pen itself: unlike a multi-dose vial, there is no measuring, no drawing up, no calculating. You dial to inject and the device stops at the correct volume automatically. That design consistency across all six strengths is worth knowing, the technique you learn on 2.5 mg carries straight through to 15 mg.

Why the pen has six strengths and what the numbers on the label actually mean

The six UK strengths (2.5, 5, 7.5, 10, 12.5 and 15 mg) each exist for a reason. The earlier doses (2.5 mg and 5 mg) are primarily about tolerability. Gastrointestinal side effects like nausea, loose stools and a general feeling of fullness are most noticeable when the medicine is new to your system or when the dose has just risen; starting low gives those effects time to settle before the therapeutic range is reached.

The numbers on the label refer to the amount of tirzepatide in each dose, not in the whole pen. A 5 mg pen contains four 5 mg doses, 20 mg total, though that figure never appears on the packaging because the relevant quantity is what you inject each week. Some people get confused comparing pens across different GLP-1 medicines; the dose numbering systems are not equivalent, so treat each product's schedule on its own terms. More on how Mounjaro's strengths compare in the guide to Mounjaro pen doses.

A question that comes up regularly: can the pen be used for fewer than four injections if you're pausing or stopping? The answer sits with your prescriber and the Patient Information Leaflet, not with us. Changing frequency, stopping early, or adjusting timing are clinical decisions, and acting on forum advice rather than prescriber guidance is where things go wrong. If you have specific questions mid-treatment, the aftercare team at nume is available seven days a week.

For those considering what the 5 mg pen specifically involves (the second step on the schedule) that page covers the transition in more detail, including what to expect when you move up from the starter dose.

What the evidence says about results at higher doses, and how that relates to the pen format

The SURMOUNT-1 trial, published in the New England Journal of Medicine, reported average body-weight reductions of around 20–21% at 15 mg tirzepatide over 72 weeks, in adults with obesity and no diabetes. Those figures come from people who reached the highest dose, and the only way to reach it is through the lower pens first.

This is worth stating plainly because some people want to know whether they can start at a higher strength. They cannot. The titration schedule exists for safety, and NICE's appraisal of tirzepatide (TA1026) endorses the licensed schedule as presented in the SmPC. Skipping steps is not something a legitimate prescriber will agree to, and any seller offering to dispatch a high-dose pen to a new patient without a full clinical history should be treated as a red flag.

The pen format supports this progression neatly: you receive exactly one month's supply at a time, your prescriber reviews your response before the next pen is authorised, and the system is designed so that dose increases require evidence. That is how it is supposed to work. If you want to understand the full picture of how weight loss develops across the dose schedule, the Mounjaro overview covers the broader clinical context.

There are also alternative formats worth knowing about. The tirzepatide multi-dose pen page explains a different pen configuration that some patients encounter; the licensed KwikPen used in the UK for weight management is the four-dose format described here, but understanding the difference is useful if you have come from another country's prescribing system or read conflicting information online.

Cost, prescriptions and what changes at each pen along the route

The price of Mounjaro in the UK varies by dose and by provider. From September 2025 Eli Lilly raised the UK list price significantly (the highest doses now carry list prices substantially higher than before) and typical private market prices across providers range roughly £149–£375 per month depending on the dose. There is more detail on what those numbers include (and often exclude) on the Mounjaro prices page.

At nume, one price covers the consultation, prescription, the pen itself, and next-working-day delivery. No subscription, no automatic renewals. Every repeat is clinically re-reviewed before a new pen is authorised, which is the correct way for a prescription medicine to be managed and is also the approach NICE's recommendation for tirzepatide (TA1026) supports, given that the guidance requires clinical review of response before continuing at any dose.

One thing worth knowing before you check eligibility: the licensed threshold for private prescribing is BMI of 30 or above, or 27 or above with at least one weight-related condition, things like high blood pressure, high cholesterol, obstructive sleep apnoea or type 2 diabetes. Lower thresholds can apply for some ethnic backgrounds per UK clinical guidance. BMI alone is not the whole picture; a prescriber weighs your full history. If you're ready to find out where you stand, you can check your eligibility with our prescribing team, the consultation is free and reviewed the same day by a real clinician, not an algorithm.